```
=> b reg;d que sta l15
FILE 'REGISTRY' ENTERED AT 17:40:51 ON 19 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   18 SEP 2007  HIGHEST RN 947490-11-1
DICTIONARY FILE UPDATES:  18 SEP 2007  HIGHEST RN 947490-11-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

L3                STR
```




```
VAR G1=8/15/16/17
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   2   7  13
NUMBER OF NODES IS  18

STEREO ATTRIBUTES: NONE
L4  (    239539) SEA FILE=REGISTRY SSS FUL L3
L5                STR
```




```
VAR G1=8/15/16/17
VAR G2=AK/20/CB/22
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS M1-X5 C  AT  20
```

GRAPH ATTRIBUTES:
RSPEC 7 13 2
NUMBER OF NODES IS 30

STEREO ATTRIBUTES: NONE
L6 (59980) SEA FILE=REGISTRY SUB=L4 SSS FUL L5
L7 STR



Cb @33 Hy @34

VAR G1=33/34
VAR G2=AK/20/CB/22
NODE ATTRIBUTES:
CONNECT IS E2 RC AT 33
CONNECT IS E2 RC AT 34
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY UNS AT 33
GGCAT IS MCY UNS AT 34
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M1-X5 C AT 20
ECOUNT IS E6 C AT 33
ECOUNT IS E5 C E1 N AT 34

GRAPH ATTRIBUTES:
RSPEC 2
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE
L8 (30343) SEA FILE=REGISTRY SUB=L6 SSS FUL L7
L9 STR



Cb @33 Hy @34



VAR G1=33/34
VAR G2=AK/20/CB/22
NODE ATTRIBUTES:
CONNECT IS E2 RC AT 33
CONNECT IS E2 RC AT 34
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY UNS AT 33
GGCAT IS MCY UNS AT 34
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M1-X5 C AT 20
ECOUNT IS E6 C AT 33
ECOUNT IS E5 C E1 N AT 34

GRAPH ATTRIBUTES:
RSPEC 4
NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE
L10 (2389) SEA FILE=REGISTRY SUB=L8 SSS FUL L9
L11 (27954) SEA FILE=REGISTRY ABB=ON PLU=ON L8 NOT L10
L12 4795 SEA FILE=REGISTRY ABB=ON PLU=ON L11 AND 46.156.30/RID
L13 STR



VAR G1=33/34
VAR G2=AK/20/CB/22
VAR G3=4/5
VAR G4=37/CHO/41
NODE ATTRIBUTES:
CONNECT IS E2 RC AT 33
CONNECT IS E2 RC AT 34
CONNECT IS E2 RC AT 42
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY UNS AT 33
GGCAT IS MCY UNS AT 34
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M1-X5 C AT 20
ECOUNT IS E6 C AT 33
ECOUNT IS E5 C E1 N AT 34

GRAPH ATTRIBUTES:
RSPEC 2
NUMBER OF NODES IS 27

STEREO ATTRIBUTES: NONE
L15 144 SEA FILE=REGISTRY SUB=L12 SSS FUL L13

100.0% PROCESSED 4491 ITERATIONS 144 ANSWERS
SEARCH TIME: 00.00.01

=> b hcap
FILE 'HCAPLUS' ENTERED AT 17:41:00 ON 19 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 19 Sep 2007 VOL 147 ISS 13
FILE LAST UPDATED: 18 Sep 2007 (20070918/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d bib abs hitstr l24 tot

L24 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:325402 HCAPLUS
DN 145:103666
TI Preparation of pyrazoles as cyclooxygenase inhibitors
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO Aust. Pat. Appl., 68 pp.
CODEN: AUXXCM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI AU2004200420	A1	20040930	2004AU-0200420	20040206 <--
PRAI 2003AU-0901100	A	20030311 <--		

OS MARPAT 145:103666
GI



I

AB The title compds. I [R1 = halo, CN, alkylcarbonyl, etc.; R2 = halo, CN, alkyl, etc.; R3 = H, alkyl; R4 = halo, CN, NO2, alkyl, etc.; or R3 and R4 may form 2,3-dihydrofuryl; R5 = OH and R6 = H in case of single bond between carbon atoms to which R5 and R6 are attached; or R5 and R6 do not exist in case of double bond; Y = CH and Z = N, Y = N and Z = CH, or Y = N and Z = N], useful for treating and/or preventing inflammatory conditions, various pains, collagen disease, autoimmune diseases, various immunity diseases, thrombosis, cancer or neurodegenerative diseases, were prepared Thus, treating a solution of 5-amino-2-methoxypyridine in 1N HCl with sodium nitrite and with tin (II) chloride dihydrate followed by addition of 4-(4,4-difluoro-3-oxobutanoyl)benzonitrile and acetic acid afforded 32% 5-(4-cyanophenyl)-3-difluoromethyl-1-(6-methoxy-3-pyridyl)-1H-pyrazole which showed IC50 of <0.01 μM against COX-1. Pharmaceutical composition comprising the compound I is disclosed.

IT **741286-77-1P 741286-88-4P 896133-10-1P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazoles as cyclooxygenase inhibitors)

RN 741286-77-1 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 741286-88-4 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-(4-methoxyphenyl)-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 896133-10-1 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-(4-cyanophenyl)-1-(6-methoxy-3-pyridinyl)-, ethyl ester (CA INDEX NAME)



IT **896133-22-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazoles as cyclooxygenase inhibitors)
RN 896133-22-5 HCAPLUS
CN 1H-Pyrazole-3-methanol, 1-(6-methoxy-3-pyridinyl)-α,α-dimethyl-5-(4-methylphenyl)- (CA INDEX NAME)



L24 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:612279 HCAPLUS
DN 143:133365
TI Preparation of pyrazole carboxamide derivatives as platelet aggregation inhibitors for treatment of ischemia
IN Kanaya, Naoaki; Ishiyama, Takashi; Muto, Ryo; Ochiai, Yuichi; Watanabe, Toshiyuki; Kuru, Noriko
PA Daiichi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 329 pp.
CODEN: PIXXD2
DT Patent
LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2005063737	A1	20050714	2004WO-JP19582	20041227 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU2004309254	A1	20050714	2004AU-0309254	20041227 <--
	CA---2551604	A1	20050714	2004CA-2551604	20041227 <--
	EP---1698626	A1	20060906	2004EP-0807937	20041227 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	CN---1902191	A	20070124	CN 2004-80039042	20041227 <--
	MX2006PA07424	A	20060913	2006MX-PA07424	20060626 <--
	NO2006003090	A	20060921	2006NO-0003090	20060704 <--
PRAI	2003JP-0434726	A	20031226 <--		
	2004JP-0012154	A	20040120 <--		
	2004JP-0321117	A	20041104		
	2004WO-JP19582	W	20041227		

OS MARPAT 143:133365

GI



I



II

AB Title compds. represented by the formula I [wherein Ar1, Ar2 = independently (un)substituted (hetero)aryl; R1 = alkyl, alkoxycarbonyl, acyl, etc.; R2 = H, alkyl; and their salts or solvates thereof] were prepared as platelet aggregation inhibitors. For example, II was given in a multi-step synthesis starting from 5-amino-2-methoxypyridine. I showed inhibition of platelet aggregation, but not for COX-1 and COX-2. Thus, I and their pharmaceutical compns. are useful prepared as platelet aggregation inhibitors for the treatment of ischemia.

IT **741286-83-9P 741287-84-3P 858598-00-2P 858598-10-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazole carboxamide derivs. as platelet aggregation inhibitors for treatment of ischemia)

RN 741286-83-9 HCAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-(6-methoxy-3-pyridinyl)-5-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 741287-84-3 HCAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-(5-methoxy-2-pyridinyl)-5-phenyl-, ethyl

ester (9CI) (CA INDEX NAME)



RN 858598-00-2 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-[3-(dimethylamino)phenyl]-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 858598-10-4 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-[4-(dimethylamino)phenyl]-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:612278 HCAPLUS
DN 143:133364
TI Preparation of pyrazole carboxamide derivatives as platelet aggregation inhibitors for treatment of ischemia
IN Horino, Haruhiko; Kanaya, Naoaki
PA Daiichi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2005063736	A1	20050714	2004WO-JP19310	20041224 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

JP2007084437 A 20070405 2003JP-0433974 20031226 <--
PRAI 2003JP-0433974 A 20031226 <--
OS MARPAT 143:133364
GI



I



II

AB Title compds. represented by the formula I [wherein Ar1, Ar2 = independently (un)substituted (hetero)aryl; R1, R2 = independently H or alkyl; R3 = H or (un)substituted alkyl; R4 = (un)substituted alkyl, amino, alkoxy, carbamoyl, heterocyclyl; n = 0 or 1; and their salts or solvates thereof] were prepared as platelet aggregation inhibitors. For example, II was given in a multi-step synthesis starting from 5-amino-2-methoxypyridine. I showed inhibition of platelet aggregation, but not for COX-1 and COX-2. Thus, I and their pharmaceutical compns. are useful as platelet aggregation inhibitors for the treatment of ischemia.

IT **741286-83-9P 741287-25-2P 858520-67-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazole carboxamide derivs. as platelet aggregation inhibitors for treatment of ischemia)

RN 741286-83-9 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-(6-methoxy-3-pyridinyl)-5-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 741287-25-2 HCAPLUS
CN 1H-Pyrazole-3-methanol, 1-(6-methoxy-3-pyridinyl)-5-phenyl- (9CI) (CA INDEX NAME)



RN 858520-67-9 HCAPLUS
CN 1H-Pyrazole-3-methanol, 1-(6-methoxy-3-pyridinyl)-α-methyl-5-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:675738 HCAPLUS
DN 141:207201
TI Preparation of pyrazole derivatives as antiplatelet aggregation agents for the treatment of ischemic diseases
IN Kanaya, Naoaki; Ishihara, Hiroaki; Kimura, Youichi; Ishiyama, Takashi; Ochiai, Yuichi
PA Daiichi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 383 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2004069824	A1	20040819	2004WO-JP01259	20040206 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU2004209495	A1	20040819	2004AU-0209495	20040206 <--
	CA---2515119	A1	20040819	2004CA-2515119	20040206 <--
	EP---1591443	A1	20051102	2004EP-0708886	20040206 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN---1759110	A	20060412	CN 2004-80006550	20040206 <--
	IN2005DN03167	A	20070525	2005IN-DN03167	20050718 <--
	NO2005003648	A	20051101	2005NO-0003648	20050727 <--
	US2006128685	A1	20060615	2005US-0543915	20050729 <--
PRAI	2003JP-0031639	A	20030207 <--		
	2003JP-0386515	A	20031117 <--		
	2004WO-JP01259	W	20040206 <--		

OS MARPAT 141:207201
GI



AB Title compds. I [Ar1 = aromatic heterocycle; Ar2 = aromatic heterocycle, etc.; R1 = II; A = cycle containing N, S, O; X = carbonyl, etc.; R3 = H, halo, etc.; R2 = H, halo, etc.] were prepared For example, N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide HCl mediated acylation of N-cyclopropylpiperazine hydrochloride with 1-(6-methoxy-3-pyridyl)-5-(2-pyridyl)pyrazole-3-carboxylic acid, e.g., prepared from 2-acetylpyridine in 3 steps, afforded compound I [Ar1 = 2-methoxypyridin-5-yl; Ar2 = 2-pyridyl; R1 = 1-cyclopropylpiperazine-4-carbonyl; R2 = H] in 83% yield. In antiplatelet activity assays, the IC50 value of compound I [Ar1 = 2-methoxypyridin-5-yl; Ar2 = 2-pyridyl; R1 = 1-cyclopropylpiperazine-4-carbonyl; R2 = H] was 0.035 μM. Of note, compds. I inhibited neither COX-1 nor COX-2. Compds. I are claimed useful for the treatment of ischemic diseases.
IT **741286-30-6P 741286-33-9P 741286-43-1P**
741286-47-5P 741286-53-3P 741286-77-1P
741286-81-7P 741286-83-9P 741286-88-4P

741286-91-9P 741286-93-1P 741286-95-3P
741287-25-2P 741287-66-1P 741287-78-5P
741287-84-3P 741291-47-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazole derivs. as antiplatelet aggregation agents for treatment of ischemic diseases)

RN 741286-30-6 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-(4-chlorophenyl)-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 741286-33-9 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-(4-ethylphenyl)-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 741286-43-1 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-(6-methoxy-3-pyridinyl)-5-(2-methylphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 741286-47-5 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-(3-fluorophenyl)-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 741286-53-3 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-(6-methoxy-3-pyridinyl)-5-[4-(phenylmethoxy)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 741286-77-1 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 741286-81-7 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-(2-fluorophenyl)-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 741286-83-9 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-(6-methoxy-3-pyridinyl)-5-phenyl-, ethyl

ester (9CI) (CA INDEX NAME)



RN 741286-88-4 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-(4-methoxyphenyl)-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 741286-91-9 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-(3-methoxyphenyl)-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 741286-93-1 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-(2-methoxyphenyl)-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 741286-95-3 HCAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-(6-methoxy-3-pyridinyl)-5-[4-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 741287-25-2 HCAPLUS
CN 1H-Pyrazole-3-methanol, 1-(6-methoxy-3-pyridinyl)-5-phenyl- (9CI) (CA INDEX NAME)



RN 741287-66-1 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-(6-chloro-3-pyridinyl)-5-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 741287-78-5 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-(4-fluorophenyl)-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 741287-84-3 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-(5-methoxy-2-pyridinyl)-5-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 741291-47-4 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-(6-methoxy-3-pyridinyl)-5-(3-methylphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



L24 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:493684 HCAPLUS
DN 141:54327
TI Preparation of pyrazole derivatives useful as COX-1 inhibitors
IN Shirai, Fumiyuki; Azami, Hidenori; Kayakiri, Natsuko; Okumura, Kazuo; Nakamura, Katsuya
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 436 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2004050632	A1	20040617	2003WO-JP14489	20031114 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA---2505945	A1	20040617	2003CA-2505945	20031114 <--
	AU2003302635	A1	20040623	2003AU-0302635	20031114 <--
	EP---1567503	A1	20050831	2003EP-0812289	20031114 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR2003016332	A	20050927	2003BR-0016332	20031114 <--
	CN---1717393	A	20060104	CN 2003-80104548	20031114 <--
	JP2006514095	T	20060427	2004JP-0570721	20031114 <--
	MX2005PA05742	A	20050816	2005MX-PA05742	20050530 <--
	IN2005CN01453	A	20070622	2005IN-CN01453	20050629 <--
	NO2005003215	A	20050901	2005NO-0003215	20050630 <--
PRAI	2002AU-0953019	A	20021202 <--		
	2002AU-0953602	A	20021230 <--		
	2003AU-0902015	A	20030429 <--		
	2003WO-JP14489	W	20031114 <--		

OS MARPAT 141:54327
GI



I

AB The compds. [I; R1 = H, alkyl; R2 = alkyl, haloalkyl, hydroxyalkyl, etc.; R3 = alkoxy, halo, CN, etc. ; R4 = H, CN, OH, etc.; X = O, S, SO, SO2; Y = CH, N; Z = alkylene, alkenylene; m = 0-1], were prepared E.g., a 3-step synthesis of 4-[3-isopropyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenol, was given. The compds. I have an inhibiting activity against COX, particularly a selective inhibiting activity against COX-1 (data for representative compds. I is given). The pharmaceutical composition comprising the compound I is claimed.

IT **705933-46-6P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazole derivs. useful as COX-1 inhibitors)

RN 705933-46-6 HCAPLUS

CN Carbamic acid, [2-[4-[3-(1-hydroxy-1-methylethyl)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **705934-45-8P 705935-79-1P 705936-08-9P**
705936-11-4P 705937-87-7P 705938-84-7P
705938-88-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazole derivs. useful as COX-1 inhibitors)

RN 705934-45-8 HCAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[4-[2-(acetyloxy)ethyl]phenyl]-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 705935-79-1 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-[4-[2-[[(1,1-dimethylethoxy)carbonyl]amino]ethoxy]phenyl]-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 705936-08-9 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-[4-(carboxymethoxy)phenyl]-1-(6-methoxy-3-pyridinyl)-, 3-ethyl ester (9CI) (CA INDEX NAME)



RN 705936-11-4 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-[4-(2-hydroxyethoxy)phenyl]-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 705937-87-7 HCAPLUS
CN Carbamic acid, [[4-[3-(1-hydroxy-1-methylethyl)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 705938-84-7 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-[4-(aminomethyl)phenyl]-1-(6-methoxy-3-pyridinyl)-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 705938-88-1 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



IT **705939-67-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazole derivs. useful as COX-1 inhibitors)
RN 705939-67-9 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-(4-hydroxyphenyl)-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:493568 HCAPLUS
DN 141:54325
TI Preparation of pyrazole derivatives useful as COX-1 inhibitors
IN Shirai, Fumiyuki; Azami, Hidenori; Kayakiri, Natsuko; Okumura, Kazuo; Nakamura, Katsuya
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO U.S. Pat. Appl. Publ., 142 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US2004116475	A1	20040617	2003US-0706999	20031114 <--
	US---7183306	B2	20070227		
	CN---1717393	A	20060104	CN 2003-80104548	20031114 <--
	US2007112037	A1	20070517	2006US-0610230	20061213 <--
PRAI	2002AU-0953019	A	20021202	<--	
	2002AU-0953602	A	20021230	<--	
	2003AU-0902015	A	20030429	<--	
	2003US-0706999	A3	20031114	<--	

OS MARPAT 141:54325
GI



I

AB The compds. [I; R1 = H, alkyl; R2 = alkyl, haloalkyl, hydroxyalkyl, etc.; R3 = alkoxy, halo, CN, etc. ; R4 = H, CN, OH, etc.; X = O, S, SO, SO2; Y = CH, N; Z = alkylene, alkenylene; m = 0-1], were prepared E.g., a 3-step synthesis of 4-[3-isopropyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenol, was given. The compds. I have an inhibiting activity against COX, particularly a selective inhibiting activity against COX-1 (data for representative compds. I is given). The pharmaceutical composition comprising the compound I is claimed.

IT **705933-46-6P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazole derivs. useful as COX-1 inhibitors)

RN 705933-46-6 HCAPLUS
CN Carbamic acid, [2-[4-[3-(1-hydroxy-1-methylethyl)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **705934-45-8P 705935-79-1P 705936-08-9P**
705936-11-4P 705937-87-7P 705938-84-7P
705938-88-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazole derivs. useful as COX-1 inhibitors)
RN 705934-45-8 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-[4-[2-(acetyloxy)ethyl]phenyl]-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 705935-79-1 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-[4-[2-[[(1,1-dimethylethoxy)carbonyl]amino]ethoxy]phenyl]-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 705936-08-9 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-[4-(carboxymethoxy)phenyl]-1-(6-methoxy-3-pyridinyl)-, 3-ethyl ester (9CI) (CA INDEX NAME)



RN 705936-11-4 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-[4-(2-hydroxyethoxy)phenyl]-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 705937-87-7 HCAPLUS
CN Carbamic acid, [[4-[3-(1-hydroxy-1-methylethyl)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 705938-84-7 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-[4-(aminomethyl)phenyl]-1-(6-methoxy-3-pyridinyl)-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 705938-88-1 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



IT **705939-67-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazole derivs. useful as COX-1 inhibitors)
RN 705939-67-9 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-(4-hydroxyphenyl)-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:279562 HCAPLUS
DN 138:304276
TI Preparation of pyrazoles as glycine transporter protein inhibitors for the treatment of neurodegenerative diseases
PA Merck Patent G.m.b.H., Germany; Yamanouchi Pharmaceutical Co.
SO Ger. Offen., 62 pp.

CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE--10149370	A1	20030410	2001DE-1049370	20011006 <--
WO2003031435	A1	20030417	2002WO-EP10172	20020911 <--
WO2003031435	A8	20030515		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU2002342675	A1	20030422	2002AU-0342675	20020911 <--
PRAI 2001DE-1049370	A	20011006 <--		
2002WO-EP10172	W	20020911 <--		

OS MARPAT 138:304276
GI



I



II



III



IV

AB Title compds. I [X = CH, N; R1 = H, A, halo, etc.; R2 = Ph, p-chlorophenyl; R3, R4 = H, (CH2)nCO2R5, CHO, etc.; R5 = H, A; A = alkyl, alkenyl, alkoxyalkyl, etc.; n = 0-5] and their pharmaceutically acceptable salts were prepared For example, condensation of enamine II e.g., prepared from 1,1-dimethoxy-N,N-dimethylmethanamine and 2-fluoro-β-oxo-benzenepropanoic acid Et ester, and aryl hydrazine III, e.g., prepared from 2-chloro-5-nitropyridine in 3-steps, provided pyrazole IV (no yield provided). In glycine transporter protein inhibition studies, approx. 71-examples of compds. I exhibited IC50 values ranging from 0.15 - 8.7 μM, e.g., the IC50 value of pyrazole IV = 2.5 μM. Compds. I are claimed useful for the treatment of schizophrenia, depression, dementia, etc.

IT **508219-76-9P**, 5-(2-Fluorophenyl)-1-(6-phenylpyridin-3-yl)-1H-pyrazol-4-carboxylic acid ethyl ester
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of pyrazoles as glycine transporter protein inhibitors for the treatment of neurodegenerative diseases)

RN 508219-76-9 HCAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 5-(2-fluorophenyl)-1-(6-phenyl-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



IT **508219-77-0P**, [5-(2-Fluorophenyl)-1-(6-phenylpyridin-3-yl)-1H-pyrazol-4-yl]methanol
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrazoles as glycine transporter protein inhibitors for the treatment of neurodegenerative diseases)
RN 508219-77-0 HCAPLUS
CN 1H-Pyrazole-4-methanol, 5-(2-fluorophenyl)-1-(6-phenyl-3-pyridinyl)- (9CI) (CA INDEX NAME)



IT **508219-82-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrazoles as glycine transporter protein inhibitors for the treatment of neurodegenerative diseases)
RN 508219-82-7 HCAPLUS
CN 1H-Pyrazole-4-carboxaldehyde, 5-(2-fluorophenyl)-1-(6-phenyl-3-pyridinyl)- (9CI) (CA INDEX NAME)



L24 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 1987:423332 HCAPLUS
DN 107:23332
TI Cyanopyrazole derivatives as intermediates for herbicides and algicides.
IN Beck, James R.
PA Eli Lilly and Co., USA
SO U.S., 10 pp. Cont.-in-part of U.S. Ser. No. 549,111, abandoned.
CODEN: USXXAM

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US---4631343	A	19861223	1984US-0650160	19840913 <--
PRAI	1983US-0549111	A2	19831107 <--		

OS CASREACT 107:23332; MARPAT 107:23332
GI



AB The title compds. [I; R1 = C5-6 cycloalkyl, 2-quinolinyl, (un)substituted Ph, 2-pyridinyl, 4-pyridinyl; R2 = C1-4 (halo)alkyl, (halo)alkoxy, halo] were prepared as intermediates for 5-cyano-1H-pyrazole-4-carboxamide herbicides (no data). 2-Hydrazinopyridine and EtOCH:C(CN)CO2Et were heated in HOAc to give pyridinylpyrazolecarboxylate II (R2 = EtO, R3 = NH2). This was chlorinated with NOCl and cyanated with NaCN to give II (R2 = EtO, R3 = cyano) which was heated with MeNH2 to give II (R2 = MeNH, R3 = cyano).

IT **98476-17-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as algicide and herbicide intermediate)

RN 98476-17-6 HCAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-(5-chloro-2-pyridinyl)-5-cyano-, ethyl ester (9CI) (CA INDEX NAME)



L24 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 1985:541948 HCAPLUS
DN 103:141948
TI Cyanopyrazole herbicides
IN Beck, James Richard
PA Eli Lilly and Co., USA
SO Brit. UK Pat. Appl., 28 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB---2149403	A	19850612	1984GB-0027972	19841105 <--
	GB---2149403	B	19871028		
	US---4589905	A	19860520	1984US-0650132	19840913 <--
	IL-----73418	A	19880229	1984IL-0073418	19841104 <--
	EP----151867	A2	19850821	1984EP-0307629	19841105 <--
	EP----151867	A3	19870401		
	EP----151867	B1	19900110		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	AT-----49404	T	19900115	1984AT-0307629	19841105 <--
	DK---8405277	A	19850508	1984DK-0005277	19841106 <--
	FI---8404348	A	19850508	1984FI-0004348	19841106 <--
	JP--60172968	A	19850906	1984JP-0235946	19841106 <--
	BR---8405645	A	19850910	1984BR-0005645	19841106 <--
	HU-----36345	A2	19850930	1984HU-0004120	19841106 <--
	HU----196112	B	19881028		
	ES----537400	A1	19860101	1984ES-0537400	19841106 <--
	ZA---8408666	A	19860129	1984ZA-0008666	19841106 <--

	CA---1227483	A1	19870929	1984CA-0467154	19841106 <--
	SU---1422996	A3	19880907	1984SU-3812255	19841106 <--
	AU---8435148	A	19850516	1984AU-0035148	19841107 <--
	AU----572913	B2	19880519		
	ES----546905	A1	19860301	1985ES-0546905	19850912 <--
	SU---1447281	A3	19881223	1986SU-4028496	19861113 <--
PRAI	1983US-0549133	A	19831107 <--		
	1984EP-0307629	A	19841105 <--		

OS CASREACT 103:141948; MARPAT 103:141948

GI



I

AB Cyanopyrazoles I [R = alkyl, cycloalkyl, 2-quinolinyl, (un)substituted Ph, 2-pyridyl, 4-pyridyl; R1, R2 = H, alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy; NR1R2 = piperidino, morpholino, pyrrolidino; X = O, S] (101 compds.) were prepared Thus, Me3CNHNH2.HCl was cyclocondensed with Me2NCH:C(COMe)CO2Et to give Et 5-methyl-1-tert-butyl-1H-pyrazole-4-carboxylate, which was brominated with NBS to give the 5-(bromomethyl) compound The latter compound, by the procedure described by H. B. Hass and M. L. Bender (1949), was converted to the 5-formyl compound, which was treated with H2NOH.HCl to give the oxime. The oxime was dehydrated with SOCl2 to give Et 5-cyano-1-tert-butyl-1H-pyrazole-4-carboxylate which was saponified to the carboxylic acid. The acid was treated with carbonyldiimidazole and MeNH2 to give I (R = Me3C, R1 = Me, R2 = H, X = O). I are useful both as preemergent and postemergent herbicides (no data).

IT **98476-17-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(amidation of)

RN 98476-17-6 HCAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-(5-chloro-2-pyridinyl)-5-cyano-, ethyl ester (9CI) (CA INDEX NAME)



=> => b uspatall
FILE 'USPATFULL' ENTERED AT 17:42:46 ON 19 SEP 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 17:42:46 ON 19 SEP 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 17:42:46 ON 19 SEP 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitstr l26 tot

L26 ANSWER 1 OF 6 USPATFULL on STN
AN 2007:128681 USPATFULL
TI Pyrazole Derivatives
IN SHIRAI, Fumiyuki, Osaka, JAPAN
Azami, Hidenori, Osaka, JAPAN
Kayakiri, Natsuko, Osaka, JAPAN
Okumura, Kazuo, Osaka, JAPAN
Nakamura, Katsuya, Osaka, JAPAN
PA FUJISAWA PHARMACEUTICAL CO., LTD., Osaka-shi, JAPAN (non-U.S. corporation)
PI US-20070112037 A1 20070517

AI 2006US-000610230 A1 20061213 (11)
RLI Division of Ser. No. 2003US-000706999, filed on 14 Nov 2003, GRANTED, Pat. No. US-----7183306
PRAI 2002AU-2002953019 20021202
2002AU-2002953602 20021230
2003AU-2003902015 20030429
DT Utility
FS APPLICATION
LREP OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940 DUKE STREET, ALEXANDRIA, VA, 22314, US
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 9883
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of the formula (I): ##STR1## wherein

R.sup.1 is hydrogen or lower alkyl;
R.sup.2 is lower alkyl, etc.;
R.sup.3 is lower alkoxy, etc.;
R.sup.4 is hydroxy, etc.; X is O, S, etc.; Y is CH or N; Z is lower alkylene or lower alkenylene; and m is 0 or 1; or salts thereof, which are useful as a medicament.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **705939-67-9P**
(preparation of pyrazole derivs. useful as COX-1 inhibitors)
RN 705939-67-9 USPATFULL
CN 1H-Pyrazole-3-carboxylic acid, 5-(4-hydroxyphenyl)-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



L26 ANSWER 2 OF 6 USPATFULL on STN
AN 2006:152244 USPATFULL
TI Pyrazole derivative
IN Kanaya, Naoaki, Tokyo, JAPAN
Ishihara, Hiroaki, Tokyo, JAPAN
Kimura, Youichi, Tokyo, JAPAN
Ishiyama, Takashi, Tokyo, JAPAN
Ochiai, Yuichi, Tokyo, JAPAN
PA DAIICHI PHARMACEUTICAL CO., LTD.,, Tokyo, JAPAN, 103-8234 (non-U.S. corporation)
PI US-20060128685 A1 20060615
AI 2004US-000543915 A1 20040206 (10)
2004WO-JP0001259 20040206
20050729 PCT 371 date
PRAI 2003JP-0000031639 20030207
2003JP-000386515 20031117
DT Utility
FS APPLICATION
LREP OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940 DUKE STREET, ALEXANDRIA, VA, 22314, US
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8901
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to a strong platelet aggregation-inhibiting agent which does not inhibit COX-1 or COX-2. The present invention provides compounds represented by formula (I) or formula (II), salts of the compounds, and solvates of the compounds or

the salts. Also provided are medicaments containing any of the compounds, salts, or solvates and preventive and/or therapeutic agents for ischemic diseases, containing any of the compounds, salts, or the solvates. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **741286-30-6P 741286-47-5P 741286-81-7P**
741286-83-9P 741286-88-4P 741286-91-9P
741286-93-1P 741287-78-5P 741287-84-3P
(preparation of pyrazole derivs. as antiplatelet aggregation agents for treatment of ischemic diseases)
RN 741286-30-6 USPATFULL
CN 1H-Pyrazole-3-carboxylic acid, 5-(4-chlorophenyl)-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 741286-47-5 USPATFULL
CN 1H-Pyrazole-3-carboxylic acid, 5-(3-fluorophenyl)-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 741286-81-7 USPATFULL
CN 1H-Pyrazole-3-carboxylic acid, 5-(2-fluorophenyl)-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 741286-83-9 USPATFULL
CN 1H-Pyrazole-3-carboxylic acid, 1-(6-methoxy-3-pyridinyl)-5-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 741286-88-4 USPATFULL
CN 1H-Pyrazole-3-carboxylic acid, 5-(4-methoxyphenyl)-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 741286-91-9 USPATFULL
CN 1H-Pyrazole-3-carboxylic acid, 5-(3-methoxyphenyl)-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 741286-93-1 USPATFULL
CN 1H-Pyrazole-3-carboxylic acid, 5-(2-methoxyphenyl)-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 741287-78-5 USPATFULL
CN 1H-Pyrazole-3-carboxylic acid, 5-(4-fluorophenyl)-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 741287-84-3 USPATFULL
CN 1H-Pyrazole-3-carboxylic acid, 1-(5-methoxy-2-pyridinyl)-5-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



L26 ANSWER 3 OF 6 USPATFULL on STN
AN 2004:152253 USPATFULL
TI Pyrazole derivatives
IN Shirai, Fumiyuki, Osaka, JAPAN
Azami, Hidenori, Osaka, JAPAN
Kayakiri, Natsuko, Osaka, JAPAN
Okumura, Kazuo, Osaka, JAPAN
Nakamura, Katsuya, Osaka, JAPAN
PA FUJISAWA PHARMACEUTICAL CO., LTD., Osaka-shi, JAPAN (non-U.S. corporation)
PI US-20040116475 A1 20040617
US-----7183306 B2 20070227
AI 2003US-000706999 A1 20031114 (10)
PRAI 2002AU-2002953019 20021202
2002AU-2002953602 20021230
2003AU-2003902015 20030429
DT Utility
FS APPLICATION
LREP OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940 DUKE STREET, ALEXANDRIA, VA, 22314
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 9237
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of the formula (I): ##STR1##

wherein R.sup.1 is hydrogen or lower alkyl;

R.sup.2 is lower alkyl, etc.;

R.sup.3 is lower alkoxy, etc.;

R.sup.4 is hydroxy, etc.;

X is O, S, etc.;

Y is CH or N;

Z is lower alkylene or lower alkenylene; and

m is 0 or 1; or salts thereof, which are useful as a medicament.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **705939-67-9P**

(preparation of pyrazole derivs. useful as COX-1 inhibitors)
RN 705939-67-9 USPATFULL
CN 1H-Pyrazole-3-carboxylic acid, 5-(4-hydroxyphenyl)-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



L26 ANSWER 4 OF 6 USPATFULL on STN
AN 86:73304 USPATFULL
TI Cyanopyrazole intermediates
IN Beck, James R., Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US-----4631343 19861223
AI 1984US-000650160 19840913 (6)
RLI Continuation-in-part of Ser. No. 1983US-000549111, filed on 7 Nov 1983, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Schwartz, Richard A.; Assistant Examiner: Briscoe, Kurt G.
LREP Page, Kathleen R. S., Jones, Joseph A.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 769
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB 5-Cyano-1-substituted-1H-pyrazole-4-carboxylic acids and esters useful as intermediates to the corresponding 4-carboxyamide derivatives having herbicidal and algicidal activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **98476-17-6P**
(preparation of, as algicide and herbicide intermediate)
RN 98476-17-6 USPATFULL
CN 1H-Pyrazole-4-carboxylic acid, 1-(5-chloro-2-pyridinyl)-5-cyano-, ethyl ester (9CI) (CA INDEX NAME)



L26 ANSWER 5 OF 6 USPATFULL on STN
AN 86:29482 USPATFULL
TI Herbicidal and algicidal 1-aryl-5-cyano-1H-pyrazole-4-carboxamides
IN Beck, James R., Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US-----4589905 19860520
AI 1984US-000650132 19840913 (6)
RLI Continuation-in-part of Ser. No. 1983US-000549133, filed on 7 Nov 1983, now abandoned
DT Utility
FS Granted

EXNAM Primary Examiner: Schwartz, Richard A.; Assistant Examiner: Briscoe, Kurt G.
LREP Page, Kathleen R. S., Barclay, Bruce J., Whale, Arthur R.
CLMN Number of Claims: 45
ECL Exemplary Claim: 1,33
DRWN No Drawings
LN.CNT 2614
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to compounds of the formula ##STR1## wherein R.sup.1 is C.sub.1 -C.sub.6 alkyl, C.sub.5 -C.sub.6 cycloalkyl, ##STR2## each of R.sup.2 and R.sup.3 is taken separately and is independently hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.4 alkenyl, C.sub.3 -C.sub.4 alkynyl, C.sub.3 -C.sub.4 cycloalkyl or C.sub.1 -C.sub.3 alkoxy, or

R.sup.2 and R.sup.3 are taken together with the nitrogen atom to which they are attached and form piperidine, morpholine or pyrrolidine;

each R.sup.4 independently is halogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -Cphd 4 alkoxy, C.sub.1 -C.sub.4 haloalkyl, C.sub.1 -C.sub.4 haloalkoxy or cyano;

X is 0 or S; and

m is 0-3;

with the provisos that when R.sup.4 is C.sub.1 -C.sub.4 alkyl, that substituent exists at other than the 2 or 6 position of the phenyl ring; and when R.sup.2 is C.sub.1 -C.sub.3 alkoxy, R.sup.3 is other than C.sub.1 -C.sub.3 alkoxy.

These compounds exhibit activity as terrestrial herbicides, aquatic herbicides, and aquatic algicides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **98476-17-6**
(amidation of)
RN 98476-17-6 USPATFULL
CN 1H-Pyrazole-4-carboxylic acid, 1-(5-chloro-2-pyridinyl)-5-cyano-, ethyl ester (9CI) (CA INDEX NAME)



L26 ANSWER 6 OF 6 USPAT2 on STN
AN 2004:152253 USPAT2
TI Pyrazole derivatives
IN Shirai, Fumiyuki, Osaka, JAPAN
Azami, Hidenori, Osaka, JAPAN
Kayakiri, Natsuko, Osaka, JAPAN
Okumura, Kazuo, Osaka, JAPAN
Nakamura, Katsuya, Osaka, JAPAN
PA Astellas Pharma Inc., Tokyo, JAPAN (non-U.S. corporation)
PI US-----7183306 B2 20070227
AI 2003US-000706999 20031114 (10)
PRAI 2002AU-2002953019 20021202
2002AU-2002953602 20021230
2003AU-2003902015 20030429
DT Utility
FS GRANTED
EXNAM Primary Examiner: Morris, Patricia L.
LREP Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 9563
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of the formula (I):

##STR1## wherein R.sup.1 is hydrogen or lower alkyl;

R.sup.2 is lower alkyl, etc.;
R.sup.3 is lower alkoxy, etc.;
R.sup.4 is hydroxy, etc.;
X is O, S, etc.;
Y is CH or N;
Z is lower alkylene or lower alkenylene; and
m is 0 or 1; or salts thereof, which are useful as a medicament.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **705939-67-9P**
(preparation of pyrazole derivs. useful as COX-1 inhibitors)
RN 705939-67-9 USPAT2
CN 1H-Pyrazole-3-carboxylic acid, 5-(4-hydroxyphenyl)-1-(6-methoxy-3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 17:07:07 ON 19 SEP 2007)

FILE 'REGISTRY' ENTERED AT 17:07:20 ON 19 SEP 2007
ACT J064C1B/A

L1 STR
L2 239539 SEA FILE=REGISTRY SSS FUL L1

ACT J064C1D/A

L3 STR
L4 (239539) SEA FILE=REGISTRY SSS FUL L3
L5 STR
L6 (59980) SEA FILE=REGISTRY SUB=L4 SSS FUL L5
L7 STR
L8 (30343) SEA FILE=REGISTRY SUB=L6 SSS FUL L7
L9 STR
L10 (2389) SEA FILE=REGISTRY SUB=L8 SSS FUL L9
L11 (27954) SEA FILE=REGISTRY ABB=ON PLU=ON L8 NOT L10
L12 4795 SEA FILE=REGISTRY ABB=ON PLU=ON L11 AND 46.156.30/RID

L13 STR L7
L14 10 L13 SAM SUB=L12
L15 144 L13 FULL SUB=L12

FILE 'HCAPLUS' ENTERED AT 17:14:47 ON 19 SEP 2007
L16 1 US20070010531/PN

FILE 'REGISTRY' ENTERED AT 17:15:07 ON 19 SEP 2007

FILE 'HCAPLUS' ENTERED AT 17:15:09 ON 19 SEP 2007
L17 TRA L16 1- RN : 174 TERMS

FILE 'REGISTRY' ENTERED AT 17:15:10 ON 19 SEP 2007
L18 174 SEA L17
L19 0 L15 AND L18

```
     FILE 'HCAPLUS' ENTERED AT 17:15:33 ON 19 SEP 2007
L20           34 L15
L21           27 L20 AND (PD<=20040310 OR AD<=20040310 OR PRD<=20040310)
                 SEL HIT RN L21

     FILE 'REGISTRY' ENTERED AT 17:17:24 ON 19 SEP 2007
L22           96 E1-96
L23           12 L22 AND (C19H19N3O4 OR C18H16FN3O3 OR C12H9CLN4O2 OR C18H17N3O3

     FILE 'HCAPLUS' ENTERED AT 17:38:15 ON 19 SEP 2007
L24            9 L23 AND L21

     FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 17:41:19 ON 19 SEP 2007
L25            6 L24
L26            6 L23

     FILE 'HCAOLD' ENTERED AT 17:42:39 ON 19 SEP 2007
L27            0 L23

     FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 17:42:46 ON 19 SEP 2007

=>
```